CML Alliance: Reviewing The Latest Recommendations In CML Management, From NCCN and ELN
CML Alliance
For Healthcare Professionals Outside the US  
 
Send to a friend Print this page Change Text Size  

About CML Alliance
Treating CML
Targeted Therapies and CML
Monitoring Treatment & Response
CML Resources
Patient Education
Guidelines & Recommendations
CML Events
CML Clinical Trials
Novartis' Commitment to the Global CML Community
CML Alliance Patient Initiative
  Access educational resources for your patients to help them better understand and manage their CML.
Learn more >

CML Targeted Therapies
  Since its development, Glivec® has been a cornerstone of therapy for CML patients.
Learn more >
 

Reviewing the Latest Recommendations in CML Management




The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 leading cancer centers in the US, publishes evidence-based clinical practice guidelines for CML. The guidelines detail specific recommendations based on patients’ cytogenetic responses to treatment, including targeted therapy.

To download the NCCN’s clinical practice guidelines for CML, click here.

The European LeukemiaNet (ELN), a not-for-profit association of scientists from 22 countries, has published recommendations proposing a schedule of response expectations at various time points of targeted therapy for Ph+ CML, including continued molecular monitoring during targeted therapy.

Learn more >

To download the ELN panel’s recommendations for CML, click here. (Subscription to Blood required for free access to full text.)

If you experience difficulties when attempting to view the above-listed documents simply right-click on the link for the document you wish to view and choose the "Save Target As" or "Save As" option. You'll be prompted for a location to save the report. Save it to a location on your computer and open the document from there.

Get the Adobe® PDF Viewer
 PDF files require the use of the Adobe® Portable Document Format (PDF) viewer available for free from the Adobe web site.

 
Novartis Oncology